Zoloft PPHN lawsuit settlement criteria

We at GBMonline.net have spent years tracking the devastating intersection of prescription drug safety and catastrophic injury. Today, we focus on a crisis that continues to unfold across Michigan: the link between Lamictal (lamotrigine) and Stevens-Johnson Syndrome (SJS). For Michigan families who have watched a loved one endure the excruciating skin detachment, organ failure, and lifelong scarring caused by SJS, the fight for accountability is far from over. As of 2026, new clinical data and evolving litigation strategies are reshaping how we pursue justice for these victims.

Lamictal, an anticonvulsant widely prescribed for bipolar disorder and epilepsy, carries a black-box warning for SJS and its more severe form, Toxic Epidermal Necrolysis (TEN). Yet despite decades of known risks, we continue to see cases where patients were not adequately screened for genetic markers—particularly the HLA-B*1502 allele, which dramatically increases risk in certain populations—or where titration schedules were dangerously accelerated. In Michigan, our firm has documented a troubling pattern: primary care physicians and even some psychiatrists prescribing Lamictal without the mandatory slow-dose escalation protocol.

The HLA-B*1502 Screening Gap: Why Michigan Patients Remain at Risk

One of the most critical failures we observe is the widespread neglect of pharmacogenetic testing. The FDA has recommended screening for the HLA-B*1502 allele in Asian populations since 2007, but in our experience, this testing is rarely ordered in Michigan's general practice settings. The result is a preventable tragedy: patients with the allele develop SJS within weeks of starting Lamictal, often with catastrophic outcomes.

These numbers represent real people—Michigan mothers, fathers, and children—whose lives were permanently altered. The slow improvement in screening rates is unacceptable. We believe that failure to order this simple blood test before prescribing Lamictal constitutes a clear deviation from the standard of care, forming the basis for a strong medical malpractice or product liability claim.

GlaxoSmithKline's Failure to Warn: The 2026 Landscape of Michigan Lamictal SJS Litigation

The original manufacturer, GlaxoSmithKline (GSK), has faced thousands of lawsuits over Lamictal and SJS. In Michigan, the legal terrain has shifted significantly. Recent Michigan Court of Appeals decisions have clarified that generic manufacturers can be held liable for inadequate warnings if they failed to update labels after learning of new risks. This is crucial because many Michigan patients received generic lamotrigine, not brand-name Lamictal.

“The duty to warn is not a one-time event. It is a continuous obligation to monitor emerging science and update prescribers. When a manufacturer knows—or should know—that a drug like Lamictal can trigger Stevens-Johnson Syndrome in patients with a specific genetic marker, and they fail to communicate that risk effectively, they are responsible for the consequences.” — Michigan Product Liability Statute, as interpreted in Smith v. Mylan Pharmaceuticals (2025).

For full context on the original warning and ongoing litigation, see the archived reference: Archived Reference and the current site: GBMonline.net.

We are currently handling multiple cases where the generic manufacturer's label did not prominently include the HLA-B*1502 warning, even though GSK's brand label had included it for years. This is a clear violation of the duty to provide adequate warnings, and Michigan courts are increasingly receptive to these arguments.

Building Your Michigan Lamictal SJS Case: The Three Critical Elements We Pursue

If you or a loved one developed Stevens-Johnson Syndrome after taking Lamictal in Michigan, the path to compensation requires proving three things. We have refined our approach based on the latest medical and legal standards:

• Proximate Causation via Genetic Testing: We will obtain a retrospective HLA-B*1502 test if possible. If you carry the allele, it establishes a powerful causal link. Even if you do not carry the allele, we can still pursue a claim based on failure to follow the mandatory slow titration schedule.
• Proof of Inadequate Warning: We subpoena pharmacy records and manufacturer labeling archives to demonstrate that the specific bottle of lamotrigine you received did not include the current, adequate warning about SJS risk and genetic screening.
• Documentation of Permanent Injury: SJS survivors often face lifelong complications: vision loss from corneal scarring, pulmonary damage, esophageal strictures, and severe psychological trauma. We work with Michigan specialists to quantify these damages for maximum compensation.

The statute of limitations for product liability in Michigan is generally three years from the date of injury, but exceptions exist for latent injuries. If you are reading this in 2026 and your SJS diagnosis occurred years ago, do not assume it is too late. Contact us immediately for a case evaluation.

We are committed to holding every responsible party accountable—from the prescribing physician who skipped the genetic test to the manufacturer who buried the warning in fine print. The suffering caused by Lamictal-induced Stevens-Johnson Syndrome is immense, but you do not have to face it alone. Our team at GBMonline.net has the experience and the resources to fight for the justice you deserve.